1 |
Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 24:29-33, 2004
DOI
ScienceOn
|
2 |
Chang Y, Ryu S, Sung E, Woo HY, Oh E, Cha K, Jung E, Kim WS. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism 57:569-576, 2008
DOI
ScienceOn
|
3 |
Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 59:1498-1509, 2001
DOI
ScienceOn
|
4 |
Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effect of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferase, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Heptol 38:434-440, 2003
DOI
ScienceOn
|
5 |
Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, Halavaara J, Yki-Jarvinen H. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87:3023-3028, 2002
DOI
ScienceOn
|
6 |
Fracanzani AL, Burdick L, Raselli S, Pedotti P, Grigore L, Santorelli G, Valenti L, Maraschi A, Catapano A, Fargion S. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am J Med 121:72-78, 2008
DOI
ScienceOn
|
7 |
Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev 22:437-443, 2006
DOI
ScienceOn
|
8 |
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844-1850, 2001
DOI
ScienceOn
|
9 |
Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917-923, 2003
DOI
ScienceOn
|
10 |
Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H, Shimazaki M, Kato T, Okuda J, Ida K. The metabolic syndrome as a predictor of non-alcoholic fatty liver disease. Ann Intern Med 143:722-728, 2005
DOI
ScienceOn
|
11 |
Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 346:1221-1231, 2002
DOI
ScienceOn
|
12 |
Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 42:132-138, 2005
|
13 |
Bugianesi E, Marchesini G, Gentilcore E, Cua IH, Vanni E, Rizzetto M, George J. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 44:1648-1655, 2006
DOI
ScienceOn
|
14 |
Gabriel A, Ziolkowski A, Radlowski P, Tomaszek K, Dziambor A. Hepatocyte steatosis in HCV patients promotes fibrosis by enhancing TGF-beta liver expression. Hepatol Res 38:141-146, 2008
|
15 |
Piche T, Vandenbos F, Abakar-Mahamat A, Vanbiervliet G, Barjoan EM, Calle G, Giudicelli J, Ferrua B, Laffont C, Benzaken S, Tran A. The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C. J Viral Hepat 11:91-96, 2004
DOI
ScienceOn
|
16 |
Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116:1413-1419, 1999
DOI
ScienceOn
|
17 |
Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33:1358-1364, 2001
DOI
ScienceOn
|
18 |
Wolf G, Chen S, Han DC, Ziyadeh FN. Leptin and renal disease. Am J Kidney Dis 39:1-11, 2002
DOI
ScienceOn
|
19 |
Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut 55:123-130, 2006
DOI
ScienceOn
|
20 |
Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH, Wahed AS. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 45:80-87, 2007
DOI
ScienceOn
|
21 |
Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 140:167-174, 2004
DOI
ScienceOn
|
22 |
Hwang ST, Cho YK, Yun JW, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI, Rhee EJ, Oh KW, Lee WY, Jin W. Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes. Intern Med J 40:437-442, 2010
DOI
ScienceOn
|
23 |
Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 28:164-176, 2005
DOI
ScienceOn
|
24 |
Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 51:714-725, 2008
DOI
ScienceOn
|
25 |
Neuschwander-Teri BA. Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 330:326-335, 2005
DOI
ScienceOn
|
26 |
Lin CC, Liu CS, Li TC, Chen CC, Li CI, Lin WY. Microalbuminuria and the metabolic syndrome and its components in the Chinese population. Eur J Clin Invest 37:783-790, 2007
DOI
ScienceOn
|
27 |
Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, Lippi G, Franchini M, Zoppini G, Muggeo M. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol 19:1564-1570, 2008
DOI
ScienceOn
|
28 |
Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 16:421-427, 2005
DOI
ScienceOn
|
29 |
Targher G, Bertolini L, Padovani R, Poli F, Scala L, Tessari R, Zenari L, Falezza G. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with nonalcoholic fatty liver disease. Diabet Med 23:403-409, 2006
DOI
ScienceOn
|
30 |
Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291:1730-1737, 2004
DOI
ScienceOn
|
31 |
Yki-Jarvinen H, Westerbacka J. The fatty liver and insulin resistance. Curr Mol Med 5:287-295, 2005
DOI
ScienceOn
|
32 |
Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109(23 Suppl 1):III27-III32, 2004
|
33 |
McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 40(Suppl 1):S17-S29, 2006
|
34 |
Pitsavos C, Panagiotakos DB, Skoumas J, Papadimitriou L, Stefanadis C. Risk stratification of apolipoprotein B, apolipoprotein A1, and apolipoprotein B/AI ratio on the prevalence of the metabolic syndrome: the ATTICA study. Angiology 59:335-341, 2008
DOI
ScienceOn
|
35 |
Lind L, Vessby B, Sundstrom J. The apolipoprotein B/AI ratio and the metabolic syndrome independently predict risk for myocardial infarction in middle-aged men. Arterioscler Thromb Vasc Biol 26:406-410, 2006
|
36 |
Holme I, Aastveit AH, Jungner I, Walldius G. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 264:30-38, 2008
DOI
ScienceOn
|
37 |
Lee JA, Jang SH, Min JH, Kim TW, Jeong WS, Shim CN, Heo WJ, Jung MJ, Lee HA, Cho YK, Hong HP. The relationship between the ApoB/ApoA-I ratio and non-alcoholic fatty liver disease in prediabetic patients. Korean J of Med 78:191-197, 2010
|
38 |
Brea A, Mosquera D, Martin E, Arizti A, Cordero JL, Ros E. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler Thromb Vasc Biol 25:1045-1050, 2005
DOI
ScienceOn
|
39 |
Kim DH, Choi SY, Park EH, Yang JI, Kim W, Kim YJ, Yoon JH, Lee HS, Shin CS, Cho SH, Oh BH. Non-alcoholic fatty liver disease (NAFLD) as a risk factor of coronary heart disease; relation of NAFLD to coronary artery calcification score by multi- detector computed tomography: The 43rd Annual Meeting of the European Association for the Study of the Liver Milan, Italy, 2008
|
40 |
Park SH, Jeon WK, Kim SH, Kim HJ, Park DI, Cho YK, Sung IK, Sohn CI, Keum DK, Kim BI. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults. J Gastroenterol Hepatol 21:138-143, 2006
DOI
ScienceOn
|
41 |
Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91-100, 2001
DOI
ScienceOn
|
42 |
Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 27:2498-2500, 2004
DOI
ScienceOn
|
43 |
Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42:473-480, 2005
DOI
ScienceOn
|
44 |
Friis-Liby I, Aldenborg F, Jerlstad P, Rundstrom K, Bjornsson E. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol 39:864-869, 2004
DOI
ScienceOn
|
45 |
Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of non-alcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol 22:1086-1091, 2007
DOI
ScienceOn
|
46 |
Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 30:2940-2944, 2007
DOI
ScienceOn
|
47 |
Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:865-873, 2006
DOI
ScienceOn
|
48 |
Adams LA, Harmsen WS, St Sauver JL, Charatcharoewitthaya P, Enders FB, Therneau T, Angulo P. Nonalcoholic fatty liver disease increase risk of death among patient with diabetes: a community-based cohort study Am J Gastroenterol 105:1567-1573, 2010
DOI
ScienceOn
|
49 |
Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 108:9-13, 2000
|